Rapid Growth but Major Risks Remain for Tilray Despite Bullish Cannabis Market
-
Revenue and alcohol sales are growing rapidly, with 34% overall revenue growth and 117% alcohol sales growth in recent quarters
-
Aim to generate positive free cash flow in fiscal 2024, which would be a major catalyst
-
Still operating at a loss and unclear if operations can sustain positive cash flow long-term
-
Original plan to access U.S. cannabis market via deal with MedMen is now very risky as MedMen struggles
-
Major risks remain even in a bull market due to reliance on uncertain factors like legalization timing and cannabis prices